Right. The market may have been kind to GILD's stock on Friday considering the run-up since the deal was announced.
Either way, replacing Riba with a more potent DAA should help.
Purine nucleotides (using PSI-938 as an example) can be more potent than GS-7977. Since ribavirin's MoA is often compared to a weak purine nucleotide, do you feel this class could make up for the shortcomings of the GS-7977/Riba combination in nulls?
Market Data 
Markets 
AI
